• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Fast Heartburn Relief Without Deadly Drugs
Since gastroesophageal reflux disease (GERD) was first identified in the early 1930s, the number of people experiencing heartburn has increased substantially. In fact, one study shows that in just 10 years, the number of people experiencing:1 Any GERD symptoms increased by 30% Symptoms at least once a week increased by 47% Severe GERD increased by 24% While these numbers are concerning, I’ll admit they’re not surprising considering the typical American diet. Our nutrition-less, grain-based diet of carbohydrates and starches has wrecked our health and made our bodies behave in ways nature never intended. This has led ...
Source: Al Sears, MD Natural Remedies - August 28, 2023 Category: Complementary Medicine Authors: Jacob Tags: Health Heart Health Natural Cures Nutrition Source Type: news

Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults
CONCLUSIONS: PPIs were associated with increased risk of ASCVD, particularly amongst participants without indications for medication. Our findings are of important practical significance and suggest that clinicians should be cautious in prophylactic use of PPIs.PMID:36113328 | DOI:10.1016/j.atherosclerosis.2022.09.001
Source: Atherosclerosis - September 16, 2022 Category: Cardiology Authors: Yue Ma Shu Li Hongxi Yang Yuan Zhang Huiping Li Lihui Zhou Jing Lin Yanchun Chen Yabing Hou Xinyu Zhang Tong Liu Xin Zhou Yaogang Wang Source Type: research

Amoxicillin/clavulanic acid-associated severe neutropenia
A 72-year-old man presented with an abnormal blood count and was admitted. His history included hypertension and hyperlipidaemia with an old myocardial infarction and mild stroke; liver cirrhosis due to non-alcoholic steatohepatitis (NASH) with hypersplenism and oesophageal varices but no ascites, oedema or bleeding; and benign prostatic hypertrophy. His medications (unchanged for years) included furosemide, spironolactone, bisoprolol, rosuvastatin, alfuzosin and omeprazole. Two weeks prior, he was discharged from our department after left leg cellulitis and Streptococcus pyogenes bacteraemia responsive to parenteral clind...
Source: Postgraduate Medical Journal - March 22, 2022 Category: General Medicine Authors: Schattner, A., Dubin, I. Tags: Adverse drug reactions Source Type: research

Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients
In conclusion, the use of clopidogrel with omeprazole is associated with an increased risk of MI, but not mortality or stroke, in this multi-ethnic Asian population. These risks appear to vary among different ethnic groups.
Source: Journal of Thrombosis and Thrombolysis - May 6, 2021 Category: Hematology Source Type: research

Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial
Publication date: 9–15 June 2018 Source:The Lancet, Volume 391, Issue 10137 Author(s): P J Devereaux, Emmanuelle Duceppe, Gordon Guyatt, Vikas Tandon, Reitze Rodseth, Bruce M Biccard, Denis Xavier, Wojciech Szczeklik, Christian S Meyhoff, Jessica Vincent, Maria Grazia Franzosi, Sadeesh K Srinathan, Jason Erb, Patrick Magloire, John Neary, Mangala Rao, Prashant V Rahate, Navneet K Chaudhry, Bongani Mayosi, Miriam de Nadal, Pilar Paniagua Iglesias, Otavio Berwanger, Juan Carlos Villar, Fernando Botto, John W Eikelboom, Daniel I Sessler, Clive Kearon, Shirley Pettit, Mukul Sharma, Stuart J Connolly, Shrikant I Bangdiwala, ...
Source: The Lancet - June 8, 2018 Category: General Medicine Source Type: research

Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE)
Conclusion MANAGE is the first randomized controlled trial to evaluate a potential treatment of patients who suffered MINS.
Source: Canadian Journal of Cardiology - February 3, 2018 Category: Cardiology Source Type: research

Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
Abstract PURPOSE: We performed a systematic review of patient-centered outcomes after the concomitant use of proton pump inhibitors (PPIs) and other drugs. METHODS: We searched 4 databases in July 2016 to find studies that reported mortality and morbidity after the concomitant use of PPIs and other drugs. We conducted direct meta-analyses using a random-effects model and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation working group approach. FINDINGS: We included data from 17 systematic reviews and meta-analyses, 16 randomized controlled t...
Source: Clinical Therapeutics - February 8, 2017 Category: Drugs & Pharmacology Authors: Shamliyan TA, Middleton M, Borst C Tags: Clin Ther Source Type: research

Long‐Term Safety of a Coordinated Delivery Tablet of Enteric‐Coated Aspirin 325 mg and Immediate‐Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk
ConclusionsLong‐term treatment with PA32540 once daily for up to 12 months in subjects at risk for aspirin‐associated UGI events is not associated with any new or unexpected safety events.
Source: Cardiovascular Therapeutics - March 3, 2016 Category: Cardiology Authors: Jay L. Goldstein, David J. Whellan, James M. Scheiman, Byron L. Cryer, Glenn M. Eisen, Angel Lanas, John G. Fort Tags: Original Research Article Source Type: research

Long‐Term Safety of a Coordinated Delivery Tablet of Enteric‐Coated Aspirin 325 mg and Immediate‐Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk
ConclusionsLong‐term treatment with PA32540 once daily for up to 12 months in subjects at risk for aspirin‐associated UGI events is not associated with any new or unexpected safety events. Clinical trials. gov identifier: NCT00995410.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 4, 2016 Category: Cardiology Authors: Jay L. Goldstein, David J. Whellan, James M. Scheiman, Byron L. Cryer, Glenn M. Eisen, Angel Lanas, John G. Fort Tags: Original Research Article Source Type: research

Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review Coronary Heart Disease
Conclusions Several frequently used PPIs previously thought to be safe for concomitant use with clopidogrel were associated with greater risk of adverse cardiovascular events. Although the data are observational, they highlight the need for randomized controlled trials to evaluate the safety of concomitant PPI and clopidogrel use in patients with coronary artery disease.
Source: JAHA:Journal of the American Heart Association - October 29, 2015 Category: Cardiology Authors: Sherwood, M. W., Melloni, C., Jones, W. S., Washam, J. B., Hasselblad, V., Dolor, R. J. Tags: Coronary Heart Disease Source Type: research

Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel vs. clopidogrel and managed without revascularization: Insights from the TRILOGY ACS Trial
Conclusions Among ACS patients managed without revascularization, use of PPIs did not result in a differential antiplatelet response between prasugrel vs. clopidogrel but was associated with a lower incidence of MI with prasugrel. These hypothesis-generating findings suggest that factors besides platelet reactivity may underlie the differential risk of MI observed by treatment assignment with PPI use.
Source: American Heart Journal - June 11, 2015 Category: Cardiology Source Type: research

Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy: Systematic Review Original Articles
Conclusions— Large, well-conducted observational studies of PPIs and randomized controlled trials of omeprazole seem to provide conflicting results for the effect of PPIs on cardiovascular outcomes when coadministered with DAPT. Prospective trials that directly compare pharmacodynamic parameters and clinical events among specific PPI agents in patients with unstable angina/non–ST-segment–elevation myocardial infarction treated with DAPT are warranted.
Source: Circulation: Cardiovascular Quality and Outcomes - January 20, 2015 Category: Cardiology Authors: Melloni, C., Washam, J. B., Jones, W. S., Halim, S. A., Hasselblad, V., Mayer, S. B., Heidenfelder, B. L., Dolor, R. J. Tags: Secondary prevention Original Articles Source Type: research

Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-β1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.
Authors: Hudzik B, Szkodzinski J, Danikiewicz A, Wilczek K, Romanowski W, Lekston A, Polonski L, Zubelewicz-Szkodzinska B Abstract BACKGROUND: Dual antiplatelet therapy (aspirin plus clopidogrel) is recommended in patients undergoing percutaneous coronary intervention (PCI). Treatment with proton pump inhibitors (PPIs) decreases bleeding rate. Alarming reports have been made that PPIs may decrease the antiplatelet activity of clopidogrel. We sought to determine whether levels of interleukin-6 (IL-6) and transforming growth factor-β1 (TGF-β1) might help distinguish individuals at risk for adverse events. METHO...
Source: European Cytokine Network - November 25, 2014 Category: Neuroscience Tags: Eur Cytokine Netw Source Type: research

Daily low-dose aspirin can prevent heart attack and stroke but is often misused
Aspirin is often hailed as a wonder drug, thanks to its ability to help stave off heart attacks and clot-caused strokes. But fewer than half of people who could benefit from a daily low-dose aspirin take it, while many others take it when they shouldn't, reports the January 2014 Harvard Heart Letter. If you don't have heart disease, but do have high blood pressure, diabetes, or other risk factors for heart disease, don't automatically assume that taking aspirin every day is a good idea. "A lot of people take aspirin who really shouldn't," says Dr. Christopher Cannon, a cardiologist at Brigham and Women's Hospital and profe...
Source: New Harvard Health Information - December 20, 2013 Category: Consumer Health News Source Type: news

Taking over the counter pain relievers safely
For aching joints or a throbbing head, millions of Americans turn to aspirin, ibuprofen (Advil, Motrin), or other nonsteroidal anti-inflammatory drugs (NSAIDs) every day. They are generally safe, but if not used carefully NSAIDs can have a dark side, according to the September 2013 Harvard Women's Health Watch. NSAIDs are widely used because they perform double duty. “They not only relieve pain, but they reduce inflammation too,” says Dr. Lucy Chen, an assistant professor at Harvard Medical School and attending physician in the anesthesia, critical care, and pain medicine department at Massachusetts General Hos...
Source: New Harvard Health Information - August 23, 2013 Category: Consumer Health News Source Type: news